Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…Abstract Number: 240 • 2018 ACR/ARHP Annual Meeting
Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
Background/Purpose: Epidemiological evidence indicates that sedentary behaviour, or “too much sitting”, is associated with poor health outcomes in the general population, including elevated systemic inflammation.…Abstract Number: 452 • 2018 ACR/ARHP Annual Meeting
Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis
Background/Purpose: OA and RA are among the most common chronic painful rheumatic diseases. Appreciation of the role of pain sensitization in OA has revolutionized the…Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…Abstract Number: 2475 • 2018 ACR/ARHP Annual Meeting
Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Background/Purpose: PROMIS (Patient Reported Outcomes Measurement Information System) has been used in rheumatoid arthritis (RA) patients (Pts) to assess disease activity across multiple domains (i.e.…Abstract Number: 499 • 2017 ACR/ARHP Annual Meeting
Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib
Background/Purpose: The purpose of this analysis was to assess whether early improvement in ACR components could act as predictors of low disease activity (LDA)…Abstract Number: 855 • 2017 ACR/ARHP Annual Meeting
Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo
Background/Purpose: Assessment of pain improvement during treatment for rheumatoid arthritis (RA) may help frame patient expectations and may be useful to clinical decision-making and discussions…Abstract Number: 856 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Chronic Opioid Use in Individuals with RA
Background/Purpose: The opioid epidemic is a major public health concern, requiring urgent action. However, little is known about chronic opioid use among individuals with RA.…Abstract Number: 858 • 2017 ACR/ARHP Annual Meeting
Identification of Clinically Relevant Pain Profiles in Individuals with Active RA
Background/Purpose: Despite DMARD treatment, many RA patients continue to suffer from pain. Defining distinct pain phenotypes may advance the use of therapies targeted at specific…Abstract Number: 2219 • 2017 ACR/ARHP Annual Meeting
Remaining Pain in DMARD-Naive Rheumatoid Arthritis Patients Treated with Baricitinib and Methotrexate
Background/Purpose: Patient (pt)-reported pain is common in rheumatoid arthritis (RA), even in pts with good disease control1. This analysis evaluated pain control achieved by methotrexate…Abstract Number: 2238 • 2017 ACR/ARHP Annual Meeting
Mapping Paindetect, a Neuropathic Pain Screening Tool, to Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Patients with Rheumatoid Arthritis: Developing a Neuropathic Pain Scale As a Measure of Treatment Outcome
Background/Purpose: To investigate relationships between painDETECT (PDQ), neuropathic pain screening tool, and patient-reported outcomes measurement information system (PROMIS) 29 in patients with rheumatoid arthritis…Abstract Number: 338 • 2017 ACR/ARHP Annual Meeting
Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis
Background/Purpose: Ongoing pain state in rheumatoid arthritis (RA) often persists after the resolution of inflammation, indicating the transition between the acute inflammatory pain and post-inflammatory…Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…